Ketamine’s Anti-Dyskinetic Effects in Female Parkinson’s Models: Preclinical Evidence and Implications

Sub-Anesthetic Ketamine Reduces Dyskinesia in Female Parkinsonian Rats

Sub-anesthetic doses of ketamine significantly reduce L-DOPA-induced dyskinesia (LID) and improve motor function in female rat models of Parkinson’s disease, according to a peer-reviewed study published on November 3, 2026 (OpenAlex W7225195074). This research directly addresses the longstanding underrepresentation of female subjects in preclinical neuropharmacology and demonstrates that ketamine’s anti-dyskinetic and anti-parkinsonian effects, previously observed in males, are robustly replicated in females.

In the study, female Sprague-Dawley rats with unilateral 6-hydroxydopamine (6-OHDA) lesions—a standard preclinical model for Parkinson’s disease—received repeated L-DOPA to induce dyskinesia, with or without adjunctive sub-anesthetic ketamine (20 mg/kg, intraperitoneal). Ketamine administration both attenuated the development of dyskinesia when given early and produced acute, significant reductions in abnormal involuntary movements (AIMs) when administered after dyskinesia had been established. Notably, these effects persisted for up to 49 days post-treatment, indicating a sustained benefit.

Mechanism and Context: Addressing Sex Differences in Neuropharmacology

Sex-based differences in neuropharmacological response are increasingly recognized as critical to translational research, yet female models remain underutilized. This study’s demonstration that ketamine’s efficacy extends to female rats fills a crucial gap, as most prior research focused on males. The findings suggest that the underlying mechanisms of ketamine’s anti-dyskinetic action—potentially involving NMDA receptor antagonism and modulation of glutamatergic signaling—are not sex-limited in this context. Importantly, ketamine did not impair the motor benefits conferred by L-DOPA, the current gold-standard therapy, and even showed independent motor improvement in forelimb stepping tests.

By confirming efficacy in both sexes, the study strengthens the translational rationale for clinical trials of ketamine in LID, a debilitating complication of long-term L-DOPA therapy in Parkinson’s disease. This insight is especially relevant as regulatory agencies and funding bodies increasingly require sex-balanced preclinical data before advancing to human trials.

Policy, Regulatory, and Research Implications

Demonstrating ketamine’s anti-dyskinetic and anti-parkinsonian effects in female models has direct implications for clinical trial design and regulatory review. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both issued guidance emphasizing the inclusion of sex as a biological variable in preclinical and clinical studies. This study provides a concrete example of how such requirements can be met, potentially expediting the investigational new drug (IND) process for ketamine repurposing in movement disorders.

• Trial Design: Future phase 1/2 trials of ketamine for LID should stratify by sex and consider sex-specific dosing or outcome measures.
• Funding and Ethics: Granting agencies may prioritize projects that address sex disparities, and institutional review boards (IRBs) may scrutinize protocols for balanced representation.
• Regulatory Pathways: The demonstration of efficacy in both sexes may facilitate dialogue with regulators regarding trial endpoints and post-market surveillance requirements.

A non-obvious implication is that the persistent anti-dyskinetic effects observed up to 49 days post-treatment suggest a potential for disease-modifying, rather than merely symptomatic, benefit—a distinction that could influence regulatory labeling and reimbursement decisions if replicated in humans.

Risks, Unknowns, and Limitations

While these preclinical findings are promising, several risks and unknowns remain. The translation of efficacy from rodent models to humans is not guaranteed, and the safety profile of repeated sub-anesthetic ketamine in Parkinson’s patients—many of whom are elderly and may have comorbidities—requires careful evaluation. Ketamine’s known risks include dissociation, cardiovascular effects, and potential for misuse, all of which must be rigorously monitored in clinical settings.

The study did not address potential sex differences in side effect profiles, nor did it explore the mechanisms underlying the sustained benefits. Additionally, the dosing regimen (20 mg/kg, i.p.) may not directly translate to human dosing, and long-term neuropsychiatric effects remain unknown. Regulatory agencies will likely require robust safety and pharmacokinetic data before approving clinical trials in this population.

Outlook: Toward Sex-Inclusive Clinical Trials for Ketamine in Parkinson’s Disease

Preclinical evidence now supports the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine in both male and female rat models, paving the way for sex-inclusive clinical research. Investigators designing early-phase trials should integrate sex as a key variable, anticipate regulatory scrutiny on this front, and plan for long-term follow-up to assess both efficacy and safety. The possibility of sustained benefit raises new questions about ketamine’s mechanism of action in neurodegenerative disease and its potential role as a disease-modifying agent, warranting further investigation.

How we research: This article was written by Dr. Alex Morgan, PhD (neuroscience), and reviewed by Dr. Priya Nair, MD, on 2026-11-06. Primary source: OpenAlex W7225195074.